A Virginia-based company has submitted plans for a substance abuse treatment program in Connecticut geared toward people who suffer from stimulant use disorders.
Affect Therapeutics, of McLean, Virginia, is proposing digitally-based services and does not have a physical location, according to a Certificate of Need application filed with the Office of Health Strategy on Wednesday.Â
The for-profit company offers comprehensive digitally-based treatment, including telehealth counseling and a smartphone app. It also offers group therapy, medical provider intervention, weekly drug screening and outreach.
Affect Therapeutics is a venture-backed company with an unused credit capacity with Silicon Valley Bank. According to Crunchbase, it recently received $16 million in Series A funding.
The company is seeking to begin offering its services statewide starting Nov. 1, according to the application. It already operates in 17 other states, according to its website.
Affect says it maintains a healthcare facility license in each state in which it operates, even though it is a fully remote company.Â
Affect uses an evidence-based approach to treating stimulant addiction, with patients going through an intensive six-month program that includes a four-hour time commitment per week. After the initial six months, it offers an open-ended maintenance program.Â
The company says the use of illegal stimulants, such as methamphetamine and cocaine, is a growing problem and that stimulant overdose deaths have increased dramatically during the last 10 years.Â
The applicant is Dr. Doug Elwood, president and CEO of Affect Provider Group.
The OHS is reviewing the application.
